Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

For Health Professionals

HIV/AIDS Research

  • The research division of the HIV Community Program was originally funded in 1989 as a site of the Community Program for Clinical Research on AIDS. The HIV Program was one of the first 17 sites in the nation.
  • The goal of the Community Program for Clinical Research on AIDS is to integrate research protocols into the primary-care setting. Under this grant more than 200 patients participated in research protocols. The successful implementation of a research agenda into primary care led to the Delaware Community Program for Clinical Research on AIDS being chosen as one of five NIAID-funded sites to participate in the civilian expansion of the Walter Reed GP-160 Vaccine Trial.

  • As a result of successful enrollment and retention of patients into these studies, the HIV Community Program broadened its focus to include pharmaceutical studies in 1994. Since that time The HIV Community Program has successfully executed more than 15 clinical protocols. These studies have included Phase II, III, and IV trials, as well as expanded-access protocols.

    The HIV Program’s excellent quality-assurance program and dedicated research staff help to ensure the timely and accurate collection of data. The implementation of research into the primary care setting helps to promote drug adherence and provides “one stop shopping” for the HIV-infected patient.

    Research coordinators prepare and coordinate the regulatory requirements of the protocols. They are available during clinic visits to assist the physicians with implementation of the protocol. In addition, they are also available to provide guidance to in-house staff when a study patient is admitted to the hospital.

  • Information about current research opportunities can be obtained by calling the HIV Community Program Office at 302-255-1300.